Localized BCNU chemotherapy and the multimodal management of malignant glioma

ABSTRACT Background: Gliomas account for 42% of all primary CNS neoplasms and 77% of all malignant primary CNS neoplasms. Unfortunately the high-grade variant of gliomas, glioblastoma multiforme (GBM), is difficult to treat and generally considered incurable. Survival rates are generally poor, and n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current medical research and opinion 2009-01, Vol.25 (1), p.149-160
Hauptverfasser: La Rocca, Renato V., Mehdorn, H. Maximilian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 160
container_issue 1
container_start_page 149
container_title Current medical research and opinion
container_volume 25
creator La Rocca, Renato V.
Mehdorn, H. Maximilian
description ABSTRACT Background: Gliomas account for 42% of all primary CNS neoplasms and 77% of all malignant primary CNS neoplasms. Unfortunately the high-grade variant of gliomas, glioblastoma multiforme (GBM), is difficult to treat and generally considered incurable. Survival rates are generally poor, and neurological morbidity in the setting of disease progression is high. Fortunately, significant progress has been achieved in the past decade in our understanding of the molecular biology of this aggressive tumour histology and, as a consequence, there is renewed clinical trial activity in this area focused on improving quality of life, treatment-related morbidity and outcomes. Methods: A review of literature from June 2005 to June 2008 was conducted on multimodal treatment of malignant glioma (MG) patients, using specific search criteria in Medline, EMBASE, and BIOSIS. Abstracts from relevant US and European medical (cancer) meetings were also evaluated. Results: The established therapies for MG include surgery, radiotherapy (RT), and local or systemic chemotherapy. However, over the last 10 years only two chemotherapeutic agents have received regulatory approval for treatment of MG: polifeprosan 20 with carmustine (BCNU implant) and temozolomide (TMZ), an imidazotetrazine derivative of dacarbazine. More recent advances in the treatment of brain tumours have been in the development of multimodal approaches. Specific interest in the combination of BCNU implant and TMZ has arisen due to the demonstrable depletion by TMZ of the DNA repair enzyme responsible for resistance to a nitrosourea such as BCNU. Further interest in this combination stems from the observation that there is a difference in the time to peak effect for each agent. Additional emerging data suggest that multimodal therapy with maximal resection and BCNU implants, followed by adjuvant therapy with radiation and TMZ, is effective and well-tolerated in patients with initial high-grade, resectable MG. Conclusions: The increasing body of efficacy data suggests that this combination of BCNU implants and TMZ within a multimodal treatment strategy including surgery and RT may provide an enhanced benefit compared with the use of either of these agents alone in select patients with high-grade glioma.
doi_str_mv 10.1185/03007990802611935
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmed_primary_19210148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19210148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-3dd534317d3025547cdca8226f8cf5fa8734f14f5cbb7bae8ed3fe2e3b9b87343</originalsourceid><addsrcrecordid>eNp9kFtLwzAUx4Mobk4_gC_SL1BNmmRJ0Rct3mDqi3sup7msHUkz0g6Zn96ODUSEPZ1z-F84_BC6JPiaEMlvMMVY5DmWOJsSklN-hMaECZoyKcQxGm_1dDDwETrruiXGJJN5fopGJM8IJkyO0dssKHDNt9HJQ_E-T1RtfOhrE2G1SaDVybAnfu36xgcNLvHQwsJ40_ZJsMPlmkULw7FwTfBwjk4suM5c7OcEzZ8eP4uXdPbx_Frcz1LFMOtTqjWnjBKhKc44Z0JpBTLLplYqyy1IQZklzHJVVaICI42m1mSGVnm11egEkV2viqHrorHlKjYe4qYkuNyiKf-hGTJXu8xqXXmjfxN7FoPhbmdoWhuih68QnS572LgQbYRWNV1JD_Xf_onXBlxfK4imXIZ1bAceB777AeVlhIE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Localized BCNU chemotherapy and the multimodal management of malignant glioma</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Taylor &amp; Francis Journals Complete</source><creator>La Rocca, Renato V. ; Mehdorn, H. Maximilian</creator><creatorcontrib>La Rocca, Renato V. ; Mehdorn, H. Maximilian</creatorcontrib><description>ABSTRACT Background: Gliomas account for 42% of all primary CNS neoplasms and 77% of all malignant primary CNS neoplasms. Unfortunately the high-grade variant of gliomas, glioblastoma multiforme (GBM), is difficult to treat and generally considered incurable. Survival rates are generally poor, and neurological morbidity in the setting of disease progression is high. Fortunately, significant progress has been achieved in the past decade in our understanding of the molecular biology of this aggressive tumour histology and, as a consequence, there is renewed clinical trial activity in this area focused on improving quality of life, treatment-related morbidity and outcomes. Methods: A review of literature from June 2005 to June 2008 was conducted on multimodal treatment of malignant glioma (MG) patients, using specific search criteria in Medline, EMBASE, and BIOSIS. Abstracts from relevant US and European medical (cancer) meetings were also evaluated. Results: The established therapies for MG include surgery, radiotherapy (RT), and local or systemic chemotherapy. However, over the last 10 years only two chemotherapeutic agents have received regulatory approval for treatment of MG: polifeprosan 20 with carmustine (BCNU implant) and temozolomide (TMZ), an imidazotetrazine derivative of dacarbazine. More recent advances in the treatment of brain tumours have been in the development of multimodal approaches. Specific interest in the combination of BCNU implant and TMZ has arisen due to the demonstrable depletion by TMZ of the DNA repair enzyme responsible for resistance to a nitrosourea such as BCNU. Further interest in this combination stems from the observation that there is a difference in the time to peak effect for each agent. Additional emerging data suggest that multimodal therapy with maximal resection and BCNU implants, followed by adjuvant therapy with radiation and TMZ, is effective and well-tolerated in patients with initial high-grade, resectable MG. Conclusions: The increasing body of efficacy data suggests that this combination of BCNU implants and TMZ within a multimodal treatment strategy including surgery and RT may provide an enhanced benefit compared with the use of either of these agents alone in select patients with high-grade glioma.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1185/03007990802611935</identifier><identifier>PMID: 19210148</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Antineoplastic Agents, Alkylating - therapeutic use ; BCNU wafer ; Brain Neoplasms - drug therapy ; Carmustine - therapeutic use ; Carmustine wafer ; Glioblastoma ; Glioma ; Glioma - drug therapy ; Humans ; Multimodal treatment ; Prognosis ; Temozolomide</subject><ispartof>Current medical research and opinion, 2009-01, Vol.25 (1), p.149-160</ispartof><rights>2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-3dd534317d3025547cdca8226f8cf5fa8734f14f5cbb7bae8ed3fe2e3b9b87343</citedby><cites>FETCH-LOGICAL-c404t-3dd534317d3025547cdca8226f8cf5fa8734f14f5cbb7bae8ed3fe2e3b9b87343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1185/03007990802611935$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1185/03007990802611935$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19210148$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>La Rocca, Renato V.</creatorcontrib><creatorcontrib>Mehdorn, H. Maximilian</creatorcontrib><title>Localized BCNU chemotherapy and the multimodal management of malignant glioma</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>ABSTRACT Background: Gliomas account for 42% of all primary CNS neoplasms and 77% of all malignant primary CNS neoplasms. Unfortunately the high-grade variant of gliomas, glioblastoma multiforme (GBM), is difficult to treat and generally considered incurable. Survival rates are generally poor, and neurological morbidity in the setting of disease progression is high. Fortunately, significant progress has been achieved in the past decade in our understanding of the molecular biology of this aggressive tumour histology and, as a consequence, there is renewed clinical trial activity in this area focused on improving quality of life, treatment-related morbidity and outcomes. Methods: A review of literature from June 2005 to June 2008 was conducted on multimodal treatment of malignant glioma (MG) patients, using specific search criteria in Medline, EMBASE, and BIOSIS. Abstracts from relevant US and European medical (cancer) meetings were also evaluated. Results: The established therapies for MG include surgery, radiotherapy (RT), and local or systemic chemotherapy. However, over the last 10 years only two chemotherapeutic agents have received regulatory approval for treatment of MG: polifeprosan 20 with carmustine (BCNU implant) and temozolomide (TMZ), an imidazotetrazine derivative of dacarbazine. More recent advances in the treatment of brain tumours have been in the development of multimodal approaches. Specific interest in the combination of BCNU implant and TMZ has arisen due to the demonstrable depletion by TMZ of the DNA repair enzyme responsible for resistance to a nitrosourea such as BCNU. Further interest in this combination stems from the observation that there is a difference in the time to peak effect for each agent. Additional emerging data suggest that multimodal therapy with maximal resection and BCNU implants, followed by adjuvant therapy with radiation and TMZ, is effective and well-tolerated in patients with initial high-grade, resectable MG. Conclusions: The increasing body of efficacy data suggests that this combination of BCNU implants and TMZ within a multimodal treatment strategy including surgery and RT may provide an enhanced benefit compared with the use of either of these agents alone in select patients with high-grade glioma.</description><subject>Antineoplastic Agents, Alkylating - therapeutic use</subject><subject>BCNU wafer</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Carmustine - therapeutic use</subject><subject>Carmustine wafer</subject><subject>Glioblastoma</subject><subject>Glioma</subject><subject>Glioma - drug therapy</subject><subject>Humans</subject><subject>Multimodal treatment</subject><subject>Prognosis</subject><subject>Temozolomide</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFtLwzAUx4Mobk4_gC_SL1BNmmRJ0Rct3mDqi3sup7msHUkz0g6Zn96ODUSEPZ1z-F84_BC6JPiaEMlvMMVY5DmWOJsSklN-hMaECZoyKcQxGm_1dDDwETrruiXGJJN5fopGJM8IJkyO0dssKHDNt9HJQ_E-T1RtfOhrE2G1SaDVybAnfu36xgcNLvHQwsJ40_ZJsMPlmkULw7FwTfBwjk4suM5c7OcEzZ8eP4uXdPbx_Frcz1LFMOtTqjWnjBKhKc44Z0JpBTLLplYqyy1IQZklzHJVVaICI42m1mSGVnm11egEkV2viqHrorHlKjYe4qYkuNyiKf-hGTJXu8xqXXmjfxN7FoPhbmdoWhuih68QnS572LgQbYRWNV1JD_Xf_onXBlxfK4imXIZ1bAceB777AeVlhIE</recordid><startdate>200901</startdate><enddate>200901</enddate><creator>La Rocca, Renato V.</creator><creator>Mehdorn, H. Maximilian</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200901</creationdate><title>Localized BCNU chemotherapy and the multimodal management of malignant glioma</title><author>La Rocca, Renato V. ; Mehdorn, H. Maximilian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-3dd534317d3025547cdca8226f8cf5fa8734f14f5cbb7bae8ed3fe2e3b9b87343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antineoplastic Agents, Alkylating - therapeutic use</topic><topic>BCNU wafer</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Carmustine - therapeutic use</topic><topic>Carmustine wafer</topic><topic>Glioblastoma</topic><topic>Glioma</topic><topic>Glioma - drug therapy</topic><topic>Humans</topic><topic>Multimodal treatment</topic><topic>Prognosis</topic><topic>Temozolomide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>La Rocca, Renato V.</creatorcontrib><creatorcontrib>Mehdorn, H. Maximilian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>La Rocca, Renato V.</au><au>Mehdorn, H. Maximilian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Localized BCNU chemotherapy and the multimodal management of malignant glioma</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2009-01</date><risdate>2009</risdate><volume>25</volume><issue>1</issue><spage>149</spage><epage>160</epage><pages>149-160</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>ABSTRACT Background: Gliomas account for 42% of all primary CNS neoplasms and 77% of all malignant primary CNS neoplasms. Unfortunately the high-grade variant of gliomas, glioblastoma multiforme (GBM), is difficult to treat and generally considered incurable. Survival rates are generally poor, and neurological morbidity in the setting of disease progression is high. Fortunately, significant progress has been achieved in the past decade in our understanding of the molecular biology of this aggressive tumour histology and, as a consequence, there is renewed clinical trial activity in this area focused on improving quality of life, treatment-related morbidity and outcomes. Methods: A review of literature from June 2005 to June 2008 was conducted on multimodal treatment of malignant glioma (MG) patients, using specific search criteria in Medline, EMBASE, and BIOSIS. Abstracts from relevant US and European medical (cancer) meetings were also evaluated. Results: The established therapies for MG include surgery, radiotherapy (RT), and local or systemic chemotherapy. However, over the last 10 years only two chemotherapeutic agents have received regulatory approval for treatment of MG: polifeprosan 20 with carmustine (BCNU implant) and temozolomide (TMZ), an imidazotetrazine derivative of dacarbazine. More recent advances in the treatment of brain tumours have been in the development of multimodal approaches. Specific interest in the combination of BCNU implant and TMZ has arisen due to the demonstrable depletion by TMZ of the DNA repair enzyme responsible for resistance to a nitrosourea such as BCNU. Further interest in this combination stems from the observation that there is a difference in the time to peak effect for each agent. Additional emerging data suggest that multimodal therapy with maximal resection and BCNU implants, followed by adjuvant therapy with radiation and TMZ, is effective and well-tolerated in patients with initial high-grade, resectable MG. Conclusions: The increasing body of efficacy data suggests that this combination of BCNU implants and TMZ within a multimodal treatment strategy including surgery and RT may provide an enhanced benefit compared with the use of either of these agents alone in select patients with high-grade glioma.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19210148</pmid><doi>10.1185/03007990802611935</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-7995
ispartof Current medical research and opinion, 2009-01, Vol.25 (1), p.149-160
issn 0300-7995
1473-4877
language eng
recordid cdi_pubmed_primary_19210148
source MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete
subjects Antineoplastic Agents, Alkylating - therapeutic use
BCNU wafer
Brain Neoplasms - drug therapy
Carmustine - therapeutic use
Carmustine wafer
Glioblastoma
Glioma
Glioma - drug therapy
Humans
Multimodal treatment
Prognosis
Temozolomide
title Localized BCNU chemotherapy and the multimodal management of malignant glioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Localized%20BCNU%20chemotherapy%20and%20the%20multimodal%20management%20of%20malignant%20glioma&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=La%20Rocca,%20Renato%20V.&rft.date=2009-01&rft.volume=25&rft.issue=1&rft.spage=149&rft.epage=160&rft.pages=149-160&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1185/03007990802611935&rft_dat=%3Cpubmed_cross%3E19210148%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19210148&rfr_iscdi=true